GWPH
GWPH Articles
London-based Jazz Pharmaceuticals has agreed to pay $7.2 billion to acquire GW Pharmaceuticals, a maker of drugs derived from cannabis plants.
Published:
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
Published:
These four off-the-radar companies are executing well, and their shares look to have very solid upside to the latest Goldman Sachs price targets.
Published:
Last Updated:
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Published:
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
Published:
GW Pharmaceuticals took a big step forward for the development of its cannabidiol product in the United Kingdom.
Published: